Mast cells comprise the major of interleukin 17-producing cells and predict a poor prognosis in hepatocellular carcinoma

Medicine (United States)

Volumn 95, Issue 13, 2016, Pages e3220-

  Tu, Jian Fei ^a   Pan, Hong Ying ^a   Ying, Xi Hui ^a   Lou, Jian ^b   Ji, Jian Song ^a   Zou, Hai ^c  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17;

ADULT; B LYMPHOCYTE; BIOSYNTHESIS; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER TUMOR; MACROPHAGE; MALE; MAST CELL; METABOLISM; MICROVASCULATURE; MIDDLE AGED; NATURAL KILLER CELL; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; T LYMPHOCYTE;

ADULT; B-LYMPHOCYTES; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-17; KAPLAN-MEIER ESTIMATE; KILLER CELLS, NATURAL; LIVER NEOPLASMS; MACROPHAGES; MALE; MAST CELLS; MICROSCOPY, FLUORESCENCE; MICROVESSELS; MIDDLE AGED; PROGNOSIS; T-LYMPHOCYTES;

EID: 84962758550     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003220     Document Type: Article

References (25)

1. Leung J, Suh WK. The CD28-B7 family in anti-tumor immunity: emerging concepts in cancer immunotherapy. Immune Netw. 2014;14:265-276.
2. Podojil JR, Miller SD. Targeting the B7 family of co-stimulatory molecules: successes and challenges. BioDrugs. 2013;27:1-13.
3. Kim S, Takahashi H, Lin WW, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457:102-106.
4. Kuang DM, Peng C, Zhao Q, et al. Tumor-activated monocytes promote expansion of IL-17-producing CD8+T cells in hepatocel-lular carcinoma patients. J Immunol. 2010;185:1544-1549.
5. Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol. 2009;183:4169-4175.
6. Huang G, Wang Y, Chi H, et al. Regulation of TH17 cell differentiation by innate immune signals. Cell Mol Immunol. 2012;9:287-295.
7. Zhu X, Mulcahy LA, Mohammed RA, et al. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 2008;10:R95.
8. Liu X, Jin H, Zhang G, et al. Intratumor IL-17-positive mast cells are the major source of the IL-17 that is predictive of survival in gastric cancer patients. PLoS One. 2014;9:e106834.
9. Ernst M, Putoczki T. IL-17 cuts to the chase in colon cancer. Immunity. 2014;41:880-882.
10. Gu K, Li MM, Shen J, et al. Interleukin-17-induced EMT promotes lung cancer cell migration and invasion via NF-kappaB/ZEB1 signal pathway. Am J Cancer Res. 2015;5:1169-1179.
11. Gu FM, Gao Q, Shi GM, et al. Intratumoral IL-17(+) cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2012;19:2506-2514.
12. Wang B, Li L, Liao Y, et al. Mast cells expressing interleukin 17 in the muscularis propria predict a favorable prognosis in esophageal squamous cell carcinoma. Cancer Immunol Immunother. 2013;62:1575-1585.
13. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361:888-898.
14. Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485-517.
15. Hueber AJ, Asquith DL, Miller AM, et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol. 2010;184:3336-3340.
16. Fitzmorris P, Shoreibah M, Anand BS, et al. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2015;141:861-876.
17. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29.
18. Liao R, Sun J, Wu H, et al. High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma. J Exp Clin Cancer Res. 2013;32:3.
19. Huang Y, Wang F, Wang Y, et al. Intrahepatic interleukin-17+T cells and FoxP3+ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:851-859.
20. Yan J, Liu XL, Xiao G, et al. Prevalence and clinical relevance of T-helper cells, Th17 and Th1, in hepatitis B virus-related hepatocel-lular carcinoma. PLoS One. 2014;9:e96080.
21. Zhang JP, Yan J, Xu J, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 2009;50:980-989.
22. Ma S, Cheng Q, Cai Y, et al. IL-17A produced by gammadelta T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res. 2014;74:1969-1982.
23. Fang J, Shing Y, Wiederschain D, et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A. 2000;97:3884-3889.
24. Mantovani A, Romero P, Palucka AK, et al. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet. 2008;371:771-783.
25. He D, Li H, Yusuf N, et al. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol. 2010;184:2281-2288.